2/17
07:52 am
xers
Xeris Biopharma to Report Full Year 2025 Financial Results and Provide Full Year 2026 Guidance on March 2, 2026 [Yahoo! Finance]
Low
Report
Xeris Biopharma to Report Full Year 2025 Financial Results and Provide Full Year 2026 Guidance on March 2, 2026 [Yahoo! Finance]
2/17
07:30 am
xers
Xeris Biopharma to Report Full Year 2025 Financial Results and Provide Full Year 2026 Guidance on March 2, 2026
Low
Report
Xeris Biopharma to Report Full Year 2025 Financial Results and Provide Full Year 2026 Guidance on March 2, 2026
1/23
05:09 am
xers
Xeris Biopharma (NASDAQ:XERS) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Medium
Report
Xeris Biopharma (NASDAQ:XERS) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
1/10
09:26 pm
xers
Is It Too Late To Consider Xeris Biopharma Holdings (XERS) After Its 133% One-Year Surge? [Yahoo! Finance]
Low
Report
Is It Too Late To Consider Xeris Biopharma Holdings (XERS) After Its 133% One-Year Surge? [Yahoo! Finance]
1/10
02:58 pm
xers
Assessing Xeris Biopharma Holdings (XERS) Valuation After Strong Recent Shareholder Returns [Yahoo! Finance]
Low
Report
Assessing Xeris Biopharma Holdings (XERS) Valuation After Strong Recent Shareholder Returns [Yahoo! Finance]
1/10
04:43 am
xers
Why Xeris Biopharma Holdings (XERS) Is Up 7.9% After Raising 2025 Revenue Outlook and Adding Patents [Yahoo! Finance]
Low
Report
Why Xeris Biopharma Holdings (XERS) Is Up 7.9% After Raising 2025 Revenue Outlook and Adding Patents [Yahoo! Finance]
1/9
08:38 am
xers
Xeris Biopharma (NASDAQ:XERS) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
Medium
Report
Xeris Biopharma (NASDAQ:XERS) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
1/8
07:27 am
xers
Xeris Expects to Deliver Record Fourth Quarter and Full-Year 2025 Total Revenue [Yahoo! Finance]
Medium
Report
Xeris Expects to Deliver Record Fourth Quarter and Full-Year 2025 Total Revenue [Yahoo! Finance]
1/8
07:00 am
xers
Xeris Expects to Deliver Record Fourth Quarter and Full-Year 2025 Total Revenue
High
Report
Xeris Expects to Deliver Record Fourth Quarter and Full-Year 2025 Total Revenue
1/2
04:15 pm
xers
Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Medium
Report
Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
1/2
12:50 am
xers
Why Xeris Biopharma Stock Zoomed 7% Higher on Wednesday [Yahoo! Finance]
Medium
Report
Why Xeris Biopharma Stock Zoomed 7% Higher on Wednesday [Yahoo! Finance]
1/1
10:55 pm
xers
US FDA declines to approve Corcept's drug for rare hormonal disorder [Yahoo! Finance]
Medium
Report
US FDA declines to approve Corcept's drug for rare hormonal disorder [Yahoo! Finance]
12/18
01:07 am
xers
Xeris Biopharma: A Balanced Perspective Needed (Rating Downgrade) [Seeking Alpha]
Low
Report
Xeris Biopharma: A Balanced Perspective Needed (Rating Downgrade) [Seeking Alpha]
12/10
07:18 am
xers
Xeris Biopharma (NASDAQ:XERS) was upgraded by analysts at Barclays PLC to a "strong-buy" rating.
Low
Report
Xeris Biopharma (NASDAQ:XERS) was upgraded by analysts at Barclays PLC to a "strong-buy" rating.
12/8
05:04 pm
xers
Xeris Biopharma (NASDAQ:XERS) is now covered by analysts at Barclays PLC. They set an "overweight" rating on the stock.
Low
Report
Xeris Biopharma (NASDAQ:XERS) is now covered by analysts at Barclays PLC. They set an "overweight" rating on the stock.
12/6
04:23 am
xers
Xeris Biopharma (XERS) Is Down 9.3% After XP-8121 Patent Milestone Is Announced – Has The Bull Case Changed? [Yahoo! Finance]
Medium
Report
Xeris Biopharma (XERS) Is Down 9.3% After XP-8121 Patent Milestone Is Announced – Has The Bull Case Changed? [Yahoo! Finance]
12/3
11:43 am
xers
What Analysts Think Is Changing The Story For Xeris Biopharma Holdings [Yahoo! Finance]
Low
Report
What Analysts Think Is Changing The Story For Xeris Biopharma Holdings [Yahoo! Finance]
12/1
07:00 am
xers
Xeris Announces Notice of Allowance from U.S. Patent and Trademark Office for XP-8121 Patent Application
Medium
Report
Xeris Announces Notice of Allowance from U.S. Patent and Trademark Office for XP-8121 Patent Application